News | March 20, 2025
Syngene concludes acquisition of biologics manufacturing facility from Emergent BioSolutions
The new site will increase Syngene's total single-use bioreactor capacity to 50,000L
The new site will increase Syngene's total single-use bioreactor capacity to 50,000L
This facility represents a significant step in Croda’s Pharma business strategy to ‘Empower biologics delivery’
The European regulator will conduct a re-inspection of the facility to verify the compliance
Overall investment in the US facility is estimated around US$50 million
This addition strengthens Dr. Agarwals Eye Hospital's vast network of 28 hospitals across Karnataka and 220+ facilities worldwide
The company will provide the necessary response on these observations to USFDA within stipulated 15 days
This is Senores' second API manufacturing facility adding significantly to the existing API manufacturing capabilities.
the inspection conducted from January 27 to January 31, 2025
Observations are largely around improvement of procedures and practices
The Alathur facility specializes in the production of Cephalosporin antibiotics
Subscribe To Our Newsletter & Stay Updated
